Iron Replacement in HHT
Iron deficiency anemia is common in people with HHT with an estimated prevalence of 50%. Further, a number of people with HHT develop symptomatic iron deficiency without anemia. Iron deficiency is an under recognized and sub-optimally managed complication in people with HHT.
Bevacizumab (Avastin) Use In HHT
Hereditary hemorrhagic telangiectasia (HHT, also known as OslerWeber-Rendu Syndrome) is a condition that is characterized by focal proliferation of blood vessels (vascular malformations) in multiple organs. Two of the most commonly affected organs include the nose and gastrointestinal tract, which lead to chronic epistaxis (nose bleeds) and GI bleeding. Bleeding in HHT patients leads to…